Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 7/20 | 0.43 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368445 | 0.86 | NTRK1 (0.51) | NTRK1SMN1; SMN2ANO1RORC | |
| SCHEMBL26186528 | 0.79 | P2RX4 (0.50) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL30285604 | 0.79 | P2RX4 (0.50) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL30382576 | 0.77 | NAMPT (0.50) | NTRK1SMN1; SMN2RORC | |
| SCHEMBL30285530 | 0.76 | P2RX4 (0.53) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL26186498 | 0.76 | P2RX4 (0.53) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL2182471 | 0.72 | WNT3A (0.62) | — | |
| SCHEMBL30285680 | 0.72 | P2RX4 (0.54) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL26186522 | 0.72 | P2RX4 (0.54) | NTRK1SMN1; SMN2ANO1 | |
| SCHEMBL30368259 | 0.70 | ANO1 (0.66) | NTRK1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |